Cancer Drug Prices Slashed by 96%: New MRP Rules Transform Access

In a notable move for cancer patients across India, the government has implemented new Maximum Retail Prices (MRP) for more than 1,000 anti-cancer formulations, effective November 9, 2026. This significant policy change is expected to save consumers an estimated ₹3,540.38 crore annually, marking a critical juncture in the accessibility of life-saving medications. The National Pharmaceutical Pricing Authority (NPPA) has capped trade margins on 137 anti-cancer drugs, with reductions reaching as high as 96.45%.

The revised pricing structure comes as a response to the pressing need for affordable cancer treatment options in India. According to the Department of Pharmaceuticals, as of November 7, 2026, 76 pharmaceutical companies had reported revised MRPs for 1,225 anti-cancer formulations, covering 121 distinct drugs. The NPPA's initiative aims to alleviate the financial burden on patients and their families, who often face exorbitant costs for essential medications.

The reduction in MRP affects 1,031 formulations, with over 600 brands reporting price cuts exceeding 50%. This comprehensive reform is designed not only to lower costs but also to enhance transparency in drug pricing. The highest reduction recorded is an impressive 96.45%, a figure that underscores the government's commitment to making cancer treatment more accessible.

To ensure compliance with the new pricing regulations, the government has introduced several mechanisms for consumers to verify drug prices. The Pharma Sahi Daam mobile application is a key tool that allows users to check the price of cancer medications easily. The app provides a platform for consumers to access the revised MRPs, ensuring that no pharmacy or chemist can charge more than the listed price.

In addition to the app, every retailer, dealer, hospital, and institution is mandated to display the revised MRP list prominently on their websites and within their premises. This initiative aims to foster a culture of transparency and accountability in the pharmaceutical sector.

Consumers are empowered to report any instances of non-compliance or price violations through multiple channels. If a pharmacy charges more than the price listed on the Pharma Sahi Daam app or printed on the medication pack, patients can lodge complaints with the NPPA. Complaints can be submitted via the app, the NPPA portal, or by calling their helpline at 1800-111-255.

For those preferring traditional methods, complaints can also be sent via post to the NPPA's Deputy Director at their New Delhi office. This multi-faceted approach to consumer protection is designed to ensure that patients receive the benefits of the new pricing structure without facing exploitation.

The implications of these new MRP regulations extend beyond just cost savings. By significantly lowering the prices of anti-cancer drugs, the government aims to improve treatment adherence among patients who may have previously struggled to afford their medications. This could lead to better health outcomes and a reduction in the overall burden of cancer in the country.

Healthcare providers are also expected to benefit from these changes. With lower drug prices, hospitals and clinics may see an increase in patient volumes as more individuals seek treatment without the fear of crippling costs. Additionally, the emphasis on compliance monitoring by State Drug Controllers will help ensure that the reforms are effectively implemented across the board.

As the government continues to prioritize healthcare reforms, the recent changes to cancer drug pricing represent a significant step forward. The NPPA's commitment to regulating trade margins and ensuring price transparency is likely to set a precedent for future healthcare policies. With the introduction of the Pharma Sahi Daam app and the requirement for pharmacies to display MRPs, patients are now better equipped to navigate the complexities of drug pricing.

Looking ahead,, the reduction of cancer drug prices by up to 96% is a monumental achievement for patient advocacy and public health in India. As these reforms take effect, the hope is that they will pave the way for more comprehensive healthcare solutions that prioritize affordability and accessibility for all.